Bringing new cures to patients is a lengthy and costly process, defined by current requirements to demonstrate safety and effectiveness. Sometimes, there are valuable new therapies for which it is not possible to determine safety and effectiveness using conventional scientific methods. This is where innovation is essential.

By leveraging our extensive regulatory expertise and cutting-edge technology, we aim to accelerate drug development in areas where conventional clinical trials are either unfeasible or hindered by prohibitive costs and lengthy timelines.

We apply novel drug development and regulatory science approaches (AI, model-informed drug development, adaptive clinical trials and Bayesian evidence of effectiveness, in vitro clinical trials)for faster cures.

Imagine if… new drugs were approved based on Phase I studies and in silico clinical trials? Sound impossible?

Contact us to find out more!